化学療法誘発性骨髄抑制(Chemotherapy Induced Myelosuppression):治療薬開発パイプライン動向(2015年上半期版)

◆英語タイトル:Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015
◆商品コード:GMDHC6451IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年3月19日
◆ページ数:42
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における化学療法誘発性骨髄抑制(Chemotherapy Induced Myelosuppression)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・化学療法誘発性骨髄抑制(Chemotherapy Induced Myelosuppression)の概要
・化学療法誘発性骨髄抑制(Chemotherapy Induced Myelosuppression)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・化学療法誘発性骨髄抑制(Chemotherapy Induced Myelosuppression)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・化学療法誘発性骨髄抑制(Chemotherapy Induced Myelosuppression)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・化学療法誘発性骨髄抑制(Chemotherapy Induced Myelosuppression)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Chemotherapy Induced Myelosuppression – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Myelosuppression – Pipeline Review, H1 2015’, provides an overview of the Chemotherapy Induced Myelosuppression’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Myelosuppression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Myelosuppression and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Myelosuppression
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chemotherapy Induced Myelosuppression and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chemotherapy Induced Myelosuppression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chemotherapy Induced Myelosuppression pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Myelosuppression
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Myelosuppression pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chemotherapy Induced Myelosuppression Overview 6
Therapeutics Development 7
Pipeline Products for Chemotherapy Induced Myelosuppression – Overview 7
Pipeline Products for Chemotherapy Induced Myelosuppression – Comparative Analysis 8
Chemotherapy Induced Myelosuppression – Therapeutics under Development by Companies 9
Chemotherapy Induced Myelosuppression – Therapeutics under Investigation by Universities/Institutes 10
Chemotherapy Induced Myelosuppression – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Chemotherapy Induced Myelosuppression – Products under Development by Companies 13
Chemotherapy Induced Myelosuppression – Products under Investigation by Universities/Institutes 14
Chemotherapy Induced Myelosuppression – Companies Involved in Therapeutics Development 15
Biothera, Inc. 15
G1 Therapeutics, Inc. 16
Chemotherapy Induced Myelosuppression – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
calcitriol – Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
G-1T28 – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
GZ-381 – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Imprime PGG – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit SHIP1 for Oncology and Immunology – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Chemotherapy Induced Myelosuppression – Recent Pipeline Updates 34
Chemotherapy Induced Myelosuppression – Dormant Projects 38
Chemotherapy Induced Myelosuppression – Product Development Milestones 39
Featured News & Press Releases 39
Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 39
Jun 12, 2012: Biothera Discovers Biomarker For The Cancer Drug Imprime PGG 40
Jun 06, 2012: Imprime PGG Binds To Adaptive Immune Cells 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

[List of Tables]
Number of Products under Development for Chemotherapy Induced Myelosuppression, H1 2015 7
Number of Products under Development for Chemotherapy Induced Myelosuppression - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Chemotherapy Induced Myelosuppression - Pipeline by Biothera, Inc., H1 2015 15
Chemotherapy Induced Myelosuppression - Pipeline by G1 Therapeutics, Inc., H1 2015 16
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 25
Chemotherapy Induced Myelosuppression Therapeutics - Recent Pipeline Updates, H1 2015 34
Chemotherapy Induced Myelosuppression - Dormant Projects, H1 2015 38

[List of Figures]
Number of Products under Development for Chemotherapy Induced Myelosuppression, H1 2015 7
Number of Products under Development for Chemotherapy Induced Myelosuppression - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Top 10 Targets, H1 2015 18
Number of Products by Stage and Top 10 Targets, H1 2015 19
Number of Products by Top 10 Mechanism of Actions, H1 2015 20
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Top 10 Routes of Administration, H1 2015 22
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23
Number of Products by Top 10 Molecule Types, H1 2015 24
Number of Products by Stage and Top 10 Molecule Types, H1 2015 25

【掲載企業】

Biothera, Inc.
G1 Therapeutics, Inc.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 化学療法誘発性骨髄抑制(Chemotherapy Induced Myelosuppression):治療薬開発パイプライン動向(2015年上半期版)(Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆